Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.
Jean‐Yves Blay(Université Claude Bernard Lyon 1), George D. Demetri(Dana-Farber Cancer Institute), Peter Reichardt(Helios Hospital Berlin-Buch), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Lee D. Cranmer(University of Washington), Thierry Alcindor(McGill University), Isabelle Ray‐Coquard(Centre Léon Bérard), Binh Bui Nguyen(Institut Bergonié), Sant P. Chawla(Sarcoma Oncology Center), Richard F. Riedel(Heidelberg University), Emmanuelle Bompas, Frank G. Haluska(Ariadne Diagnostics (United States)), Mohammed Milhem(University of Iowa), P. Dodion(Dana-Farber/Harvard Cancer Center), Arthur P. Staddon(University of Pennsylvania), Axel Le Cesne(Institut Gustave Roussy), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yang Song(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel A. Rushing(Dana-Farber/Harvard Cancer Center)
Cited by 11
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k